<DOC>
	<DOC>NCT01722331</DOC>
	<brief_summary>This study is being conducted to evaluate the efficacy and safety/tolerability of subcutaneous MK-3222, followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic plaque psoriasis.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Clinical diagnosis of moderatetosevere plaque psoriasis for at least 6 months prior to study enrollment A candidate for phototherapy or systemic therapy For the extension study: must have completed Part 3 of the base study For the extension study: must have achieved at least a PASI50 response by the end of Part 3 of the base study For the extension study: must have received active MK3222 treatment within 12 weeks prior to the end of Part 3 of the base study Premenopausal female participants must agree to abstain from heterosexual activity or use a medically accepted method of contraception or use appropriate effective contraception as per local regulations or guidelines If enrolled at a Japanese site, participants with psoriatic arthritis using nonsteroidal antiinflammatory drugs (NSAIDs) must be on a stable dose for at least 4 weeks prior to the first dose of study drug and must not be expected to require an increase in dose over the course of the study Has erythrodermic psoriasis, predominantly pustular psoriasis, medicationinduced or medicationexacerbated psoriasis, or new onset guttate psoriasis Current or history of severe psoriatic arthritis and is wellcontrolled on current treatment Women of childbearing potential that are pregnant, intend to become pregnant within 6 months of completing the trial, or that are breast feeding Expected to require topical treatment, phototherapy, or systemic treatment during the trial Presence of any infection History of recurrent infection requiring treatment with systemic antibiotics within 2 weeks of screening Previous use of MK3222 or other IL23/Th17 pathway inhibitors including P40, p19, and IL17 antagonists Evidence of active or untreated latent tuberculosis (TB) Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBs Ag) or hepatitis C virus (HCV) At Japanese sites, positive test for HBs antibody and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) At Japanese sites, positive test for the Hepatitis B core (HBc) antibody and HBV DNA For the extension study: women of childbearing potential that are pregnant, intend to become pregnant within 6 months of completing the trial, or that are breast feeding For the extension study: active or uncontrolled significant organ dysfunction or clinically significant laboratory abnormalities For the extension study: expected to require topical treatment, phototherapy, or systemic treatment during the extension study At Japanese sites, abnormal for Beta D Glucan and/or KL6 test result(s) at the screening visit.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>